Crohn’s Disease (CD) is characterized by inflammation (the changes that happen when tissues in the body are injured) and ulceration (open sore) of the small and/or large intestines. Ulcerative colitis(UC)s is characterized by inflammation of the large intestine (colon). Indeterminate colitis (IC) is a sub-group of inflammatory bowel disease that cannot be characterized as either CD or UC. Patients with CD, UC and IC suffer from symptoms such as diarrhea, abdominal pain, rectal bleeding, weight loss, difficulty growing and fever. CD, UC and IC can be treated with medications that suppress the immune system (the body system involved in inflammations and infections), or in some cases surgery. This research study is an observational research study (a registry) designed to gain information on pediatric patients with inflammatory bowel disease (IBD).
The purpose of the study is to obtain long-term safety information on participants disease and medications that participants received or are receiving for his/her inflammatory bowel disease.
Patients under 17 years of age at the time of study enrollment diagnosed with Inflammatory Bowel Disease at least 2 months.
Participants will be patients of the Digestive Diseases and Nutrition Center at Women & Children’s Hospital of Buffalo and will have biannual direct contact preferably a medical encounter(office visit) and review of participant’s medical record where the following will be collected: subject’s height, weight, information about participant’s disease and completion of a Quality of Life Questionnaire.
Subjects will receive $20 for each Quality of Life Questionnaire that is completed (biannually).
Susan S. Baker, MD, PhD, Principal Investigator Robert D. Baker, MD, PhD, Sub-Investigator Daniel Gelfond, MD, Sub-Investigator Humaira Hashmi, MD, Sub-Investigator Anita M. Crawley, RN, PNP, Sub-Investigator Casey Gajewski, RN, PNP, Sub-Investigator
Name: Susan S. Baker, MD, PhD or Christine M. Roach, RN, BSN, Study Coordinator